摘要
目的探讨SYNTAXⅡ评分系统(SS-Ⅱ)对接受经皮冠状动脉介入治疗(PCI)的急性冠状动脉综合征(ACS)患者12个月临床预后的预测价值。方法选取北部战区总医院自2016年3月至2019年3月收治的接受PCI且可计算SS-Ⅱ评分的16667例ACS患者为研究对象。根据SS-Ⅱ评分中位数将患者分入3组,分别为SS-Ⅱ低分组(评分≤45.43分,n=5555)、SS-Ⅱ中分组(评分45.43~53.70分,n=5556)、SS-Ⅱ高分组(评分≥53.70分,n=5556)。比较3组患者术后12个月的终点事件发生率。结果SS-Ⅱ高分组缺血事件、缺血事件独立组成成分(心性死亡、心肌梗死、卒中)、全因死亡发生率高于SS-Ⅱ低分组和SS-Ⅱ中分组,差异有统计学意义(P<0.05)。SS-Ⅱ中分组和SS-Ⅱ高分组出血学会研究联合会(BARC)3,5出血事件发生率高于SS-Ⅱ低分组,差异有统计学意义(P<0.05)。3组BARC 2,3,5出血事件发生率比较,差异无统计学意义(P>0.05)。结论SS-Ⅱ评分是预测ACS患者PCI术后12个月临床预后的良好工具,SS-Ⅱ评分越高,患者预后越差。
Objective To investigate the predictive ability of SYNTAX scoring systemⅡ(SS-Ⅱ)for clinical prognosis of patients with acute coronary syndrome(ACS)undergoing percutaneous coronary interventions(PCI).Methods A total of 16667 ACS patients receiving PCI and calculable SS-Ⅱscore from March 2016 to March 2019 in General Hospital of Northern Theater Command were selected as the study subjects.According to the median SS-Ⅱscore,patients were divided into 3 groups:SS-Ⅱscore low group(score≤45.43,n=5555),SS-Ⅱscore medium group(score 45.43-53.70,n=5556),SS-Ⅱscore high group(score≥53.70,n=5556).The incidence of end point events 12 months after surgery was compared among 3 groups.Results The incidence of ischemic events,independent components of ischemic events(cardiac death,myocardial infarction,stroke)and all-cause death in SS-Ⅱscore high group were higher than those in SS-Ⅱscore low group and SS-Ⅱscore medium group,and the difference was statistically significant(P<0.05).The incidence of bleeding academic research consortium(BARC)3,5 bleeding events in SS-Ⅱscore medium group and SS-Ⅱscore high group was significantly higher than that in SS-Ⅱscore low group(P<0.05).There was no significant difference in the incidence of BARC 2,3,5 bleeding events among the 3 groups(P>0.05).Conclusion SS-Ⅱscore is a good tool to predict the clinical prognosis of ACS patients 12 months after PCI.The higher SS-Ⅱscore is,the worse the prognosis is.
作者
武洋
裘淼涵
那堃
李晶
韩雅玲
李毅
WU Yang;QIU Miao-han;NA Kun;LI Jing;HAN Ya-ling;LI Yi(Department of Cardiology,General Hospital of Northern Theater Command,Shenyang 110016,China;Shenyang Pharmaceutical University,Shenyang 110016,China)
出处
《临床军医杂志》
CAS
2021年第10期1074-1078,共5页
Clinical Journal of Medical Officers
基金
国家十三五重点研发计划(2016YFC1301303)。